Literature DB >> 24876565

Molecular liaisons between erythropoiesis and iron metabolism.

Leon Kautz1, Elizabeta Nemeth1.   

Abstract

Although most circulating iron in blood plasma is destined for erythropoiesis, the mechanisms by which erythropoietic demand modulates the iron supply ("erythroid regulators") remain largely unknown. Iron absorption, plasma iron concentrations, and tissue iron distribution are tightly controlled by the liver-produced hormone hepcidin. During the last decade, much progress has been made in elucidating hepcidin regulation by iron and inflammation. This review discusses the less understood mechanisms and mediators of hepcidin suppression in physiologically and pathologically stimulated erythropoiesis.
© 2014 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24876565      PMCID: PMC4110655          DOI: 10.1182/blood-2014-05-516252

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  33 in total

1.  Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice.

Authors:  Sara Gardenghi; Pedro Ramos; Maria Franca Marongiu; Luca Melchiori; Laura Breda; Ella Guy; Kristen Muirhead; Niva Rao; Cindy N Roy; Nancy C Andrews; Elizabeta Nemeth; Antonia Follenzi; Xiuli An; Narla Mohandas; Yelena Ginzburg; Eliezer A Rachmilewitz; Patricia J Giardina; Robert W Grady; Stefano Rivella
Journal:  J Clin Invest       Date:  2010-11-22       Impact factor: 14.808

2.  Stimulated erythropoiesis with secondary iron loading leads to a decrease in hepcidin despite an increase in bone morphogenetic protein 6 expression.

Authors:  David M Frazer; Sarah J Wilkins; Deepak Darshan; Alison C Badrick; Gordon D McLaren; Gregory J Anderson
Journal:  Br J Haematol       Date:  2012-03-26       Impact factor: 6.998

3.  Expression of growth differentiation factor 15 is not elevated in individuals with iron deficiency secondary to volunteer blood donation.

Authors:  Toshihiko Tanno; Antoinette Rabel; Y Terry Lee; Yu Ying Yau; Susan F Leitman; Jeffery L Miller
Journal:  Transfusion       Date:  2010-02-26       Impact factor: 3.157

4.  Regulation of hepcidin expression at high altitude.

Authors:  Nick P Talbot; Samira Lakhal; Thomas G Smith; Catherine Privat; Annabel H Nickol; Maria Rivera-Ch; Fabiola León-Velarde; Keith L Dorrington; David R Mole; Peter A Robbins
Journal:  Blood       Date:  2011-11-30       Impact factor: 22.113

5.  Erythropoietin, GDF15, IL6, hepcidin and testosterone levels in a large cohort of elderly individuals with anaemia of known and unknown cause.

Authors:  Jill Waalen; Katharina von Löhneysen; Pauline Lee; Xiuling Xu; Jeffrey S Friedman
Journal:  Eur J Haematol       Date:  2011-08       Impact factor: 2.997

Review 6.  Hepcidin and disorders of iron metabolism.

Authors:  Tomas Ganz; Elizabeta Nemeth
Journal:  Annu Rev Med       Date:  2011       Impact factor: 13.739

7.  Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin.

Authors:  Damien R Ashby; Daniel P Gale; Mark Busbridge; Kevin G Murphy; Neill D Duncan; Tom D Cairns; David H Taube; Stephen R Bloom; Frederick W K Tam; Richard Chapman; Patrick H Maxwell; Peter Choi
Journal:  Haematologica       Date:  2009-10-14       Impact factor: 9.941

8.  Regulation of growth differentiation factor 15 expression by intracellular iron.

Authors:  Samira Lakhal; Nick P Talbot; Alexi Crosby; Chantal Stoepker; Alain R M Townsend; Peter A Robbins; Christopher W Pugh; Peter J Ratcliffe; David R Mole
Journal:  Blood       Date:  2008-12-01       Impact factor: 22.113

9.  Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells.

Authors:  Toshihiko Tanno; Prashanth Porayette; Orapan Sripichai; Seung-Jae Noh; Colleen Byrnes; Ajoy Bhupatiraju; Y Terry Lee; Julia B Goodnough; Omid Harandi; Tomas Ganz; Robert F Paulson; Jeffery L Miller
Journal:  Blood       Date:  2009-05-04       Impact factor: 22.113

10.  Hepcidin levels and their determinants in different types of myelodysplastic syndromes.

Authors:  Valeria Santini; Domenico Girelli; Alessandro Sanna; Nicola Martinelli; Lorena Duca; Natascia Campostrini; Agostino Cortelezzi; Michela Corbella; Alberto Bosi; Gianluigi Reda; Oliviero Olivieri; Maria Domenica Cappellini
Journal:  PLoS One       Date:  2011-08-19       Impact factor: 3.240

View more
  33 in total

1.  Erythroferrone contributes to hepcidin suppression and iron overload in a mouse model of β-thalassemia.

Authors:  Léon Kautz; Grace Jung; Xin Du; Victoria Gabayan; Justin Chapman; Marc Nasoff; Elizabeta Nemeth; Tomas Ganz
Journal:  Blood       Date:  2015-08-14       Impact factor: 22.113

2.  Deregulated iron metabolism in bone marrow from adenine-induced mouse model of chronic kidney disease.

Authors:  Tomoko Kimura; Takahiro Kuragano; Kiyoko Yamamoto; Masayoshi Nanami; Yukiko Hasuike; Takeshi Nakanishi
Journal:  Int J Hematol       Date:  2018-09-19       Impact factor: 2.490

3.  Bitopertin, a selective oral GLYT1 inhibitor, improves anemia in a mouse model of β-thalassemia.

Authors:  Alessandro Matte; Enrica Federti; Michael Winter; Annette Koerner; Anja Harmeier; Norman Mazer; Tomas Tomka; Maria Luisa Di Paolo; Luigia De Falco; Immacolata Andolfo; Elisabetta Beneduce; Achille Iolascon; Alejandra Macias-Garcia; Jane-Jane Chen; Anne Janin; Christhophe Lebouef; Franco Turrini; Carlo Brugnara; Lucia De Franceschi
Journal:  JCI Insight       Date:  2019-11-14

Review 4.  Intracellular iron and heme trafficking and metabolism in developing erythroblasts.

Authors:  Martin D Kafina; Barry H Paw
Journal:  Metallomics       Date:  2017-09-20       Impact factor: 4.526

5.  Erythropoietin's inhibiting impact on hepcidin expression occurs indirectly.

Authors:  Elena Gammella; Victor Diaz; Stefania Recalcati; Paolo Buratti; Michele Samaja; Soumyadeep Dey; Constance Tom Noguchi; Max Gassmann; Gaetano Cairo
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2014-12-17       Impact factor: 3.619

6.  Reversal of hemochromatosis by apotransferrin in non-transfused and transfused Hbbth3/+ (heterozygous B1/B2 globin gene deletion) mice.

Authors:  Monique P Gelderman; Jin Hyen Baek; Ayla Yalamanoglu; Michele Puglia; Florence Vallelian; Bo Burla; Jaroslav Vostal; Dominik J Schaer; Paul W Buehler
Journal:  Haematologica       Date:  2015-01-23       Impact factor: 9.941

Review 7.  Excess iron: considerations related to development and early growth.

Authors:  Marianne Wessling-Resnick
Journal:  Am J Clin Nutr       Date:  2017-10-25       Impact factor: 7.045

Review 8.  Modern iron replacement therapy: clinical and pathophysiological insights.

Authors:  Domenico Girelli; Sara Ugolini; Fabiana Busti; Giacomo Marchi; Annalisa Castagna
Journal:  Int J Hematol       Date:  2017-12-01       Impact factor: 2.490

Review 9.  Hepcidin in the diagnosis of iron disorders.

Authors:  Domenico Girelli; Elizabeta Nemeth; Dorine W Swinkels
Journal:  Blood       Date:  2016-04-04       Impact factor: 22.113

10.  Single versus Split Dose of Iron Optimizes Hemoglobin Mass Gains at 2106 m Altitude.

Authors:  Rebecca Hall; Peter Peeling; Elizabeta Nemeth; Dan Bergland; Walter T P McCluskey; Trent Stellingwerff
Journal:  Med Sci Sports Exerc       Date:  2019-04       Impact factor: 5.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.